Thus, inhibitors have been developed and are available to target various components of this signaling pathway with the goal of restoring antiestrogen sensitivity in aromatase inhibitor resistant breast cancer cells (1, 204–206). This evidence concerns the gene CYP19A1 and breast carcinoma.